Posterior reversible encephalopathy syndrome in patients with COVID-19
| Autor: | Neal S. Parikh, Virginia Gao, Sarah C. Parauda, Alan Z. Segal, Alexandra N. Gewirtz, Babak B. Navi, Alexander E Merkler, Dana Leifer, Joshua E Lantos, Halina White |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty medicine.medical_treatment Clinical Neurology Systemic inflammation Article law.invention 03 medical and health sciences Lethargy 0302 clinical medicine law medicine Humans 030212 general & internal medicine Aged Retrospective Studies Mechanical ventilation SARS-CoV-2 business.industry Medical record COVID-19 Posterior reversible encephalopathy syndrome Retrospective cohort study Middle Aged medicine.disease Intensive care unit Neurology Posterior Leukoencephalopathy Syndrome Female Neurology (clinical) medicine.symptom business 030217 neurology & neurosurgery |
| Zdroj: | Journal of the Neurological Sciences |
| ISSN: | 0022-510X |
| DOI: | 10.1016/j.jns.2020.117019 |
| Popis: | Objective To report four patients with coronavirus disease 2019 (COVID-19) who developed posterior reversible encephalopathy syndrome (PRES). Methods Patient data was abstracted from medical records at Weill Cornell Medical Center. Results Four patients with SARS-CoV-2 infection and PRES were identified. The patients' ages ranged from 64 to 74 years, and two were women. All four patients were admitted to the hospital with acute respiratory distress syndrome requiring intensive care unit admission and mechanical ventilation. PRES was diagnosed after persistent confusion, lethargy, new focal neurological deficits, or seizures were noted, with evidence of seizures on electroencephalogram for two of the patients. Imaging confirmed the presence of cerebral vasogenic edema. All four patients had elevated blood pressure and renal injury in the days preceding PRES diagnosis, as well as evidence of systemic inflammation and systemic hypercoagulability. Symptoms of PRES improved with blood pressure control. Conclusions Our four cases demonstrate the occurrence of PRES in critically-ill patients with COVID-19. PRES should be considered in the differential for acute neurological deficits and seizures in this setting. Highlights • We report four patients with COVID-19 COVID 19 who developed posterior reversible encephalopathy syndrome (PRES). • PRES was diagnosed in the context of persistent confusion, lethargy, focal neurologic deficits and seizure. • All patients had acute hypertension, renal injury,evidence of systemic inflammation and hypercoagulability. • PRES should be considered in patients with neurological symptoms and COVID-19 to ensure early treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect